By Dr. Donald L. Gates, MD
Compounded GLP-1 quality is a fair thing to ask about. You are injecting a medication into your body every week. You are entitled to know where it came from, who made it, and how anyone verified it.
Compounded medications serve real clinical purposes. A patient with a documented allergy to an inactive ingredient, or a need for a formulation that no approved product provides, may genuinely benefit from one. But compounded drugs are not FDA-approved. The agency does not review them for safety, effectiveness, or quality before they are marketed.
The 2026 Regulatory Picture
Two things changed the landscape.
First, the FDA has declared the national shortages of semaglutide and tirzepatide injections resolved. The shortage was the legal basis that allowed compounders to produce what amounted to copies of approved drugs at scale. That basis has ended.
Second, enforcement escalated sharply. The FDA has issued warning letters to dozens of telehealth companies over marketing claims for compounded GLP-1s. The FBI issued a public fraud alert in February 2025 regarding counterfeit and fraudulent products.
The FDA’s current position is narrow: compounded GLP-1 drugs should be used only when a patient’s medical needs cannot be met by an FDA-approved drug. Price is not a medical need.
The 10 Questions
1. Is this medication FDA-approved or compounded? The answer should be one word, immediately. A compounded product should never be described as “generic Ozempic,” “generic Wegovy,” “generic Mounjaro,” or as the same thing as an approved drug. Those descriptions are not accurate.
2. Why is a compounded medication being considered for me specifically? The explanation should name the patient-specific medical need that an available FDA-approved product cannot meet. Cost alone does not convert a mass-produced copy into a patient-specific preparation.
3. What is the pharmacy’s exact legal name? It should appear on the label. Verify it with the state board of pharmacy. Be careful when the name is missing, unfamiliar, or cannot be found in a licensing database.
4. Is this a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility? These are different regulatory pathways. A 503B outsourcing facility registers with the FDA, operates under current Good Manufacturing Practices, and appears on a public FDA list that includes inspection history. A 503A pharmacy is regulated primarily by its state board. Neither status means the FDA approved the product.
5. What exact ingredient form is used? This question matters more than most patients realize. The FDA has specifically warned about semaglutide sodium and semaglutide acetate. These are salt forms that differ from the base form used in FDA-approved products, and FDA guidance indicates they lack a lawful basis for use in compounding. Ask for the full ingredient name, not just the word “semaglutide.”
6. What quality documentation exists? Ask how the pharmacy qualifies its ingredient suppliers, and what testing it performs for identity, potency, sterility, and endotoxins. A certificate of analysis is only meaningful when it ties to your specific lot and comes from a credible independent laboratory.
7. Can the vial be traced by lot? The label should carry a lot or batch identifier, a beyond-use date, the concentration, pharmacy contact information, and your name as the prescription patient.
8. What is the concentration, and is my dose written in milligrams? “Units” describe syringe volume. They do not describe drug mass. The FDA has received reports of patients administering five to twenty times their intended dose because of confusing concentration labeling on compounded vials, in some cases requiring hospitalization. Your prescription, your label, and your injection teaching should make the relationship between milligrams, milliliters, and syringe markings unmistakable.
9. How is temperature controlled during shipping? The FDA has received complaints about compounded GLP-1 drugs arriving warm or with inadequate ice packs. The agency advises patients not to use injectable GLP-1 medication that arrives with compromised temperature control. Ask in advance what to do if the packaging is damaged.
10. Who answers questions about the product itself? Clinical symptoms go to your prescriber. Damaged shipments, replacement requests, and suspected quality problems go to the dispensing pharmacy. You should have both numbers before your first dose.
What the Testing Data Shows
This is not a hypothetical concern. Published research on semaglutide purchased from unregulated online sources found purity levels of 7% to 14%, against labels claiming 99%. The same research found the actual semaglutide content exceeded the labeled dose by 28% to 39%.
Those findings apply to unregulated online sellers, not to every compounding pharmacy. That distinction is important and it cuts both ways. It means a licensed, accredited compounder is a genuinely different proposition. It also means the label alone tells you nothing.
Frequently Asked Questions
Is compounded semaglutide safe?
Compounded semaglutide is not FDA-approved, and safety depends heavily on the pharmacy that prepared it. Published analyses of FDA adverse event data have found higher reporting rates for serious events with compounded formulations than with approved products. Discuss the specific product and pharmacy with your physician.
Is a licensed pharmacy the same as FDA approval?
No. Pharmacy licensure and FDA registration are not FDA approval of the product. A 503B outsourcing facility is registered and inspected, but each preparation it produces is still not an FDA-approved drug.
Should I bring my current vial to an appointment?
Yes. Bring the vial, the box, and the pharmacy paperwork. The ingredient form, concentration, lot number, and beyond-use date on that label answer several of these ten questions at once.
This article is educational and is not a substitute for individualized medical advice. Treatment decisions depend on your medical history, current medications, and clinical circumstances. Talk with a physician before starting, changing, or stopping any medication. If symptoms are severe, rapidly worsening, or feel like an emergency, call 911 or seek emergency care.
About the Author: Dr. Donald L. Gates, MD leads Scale Solutions, a medical weight management practice serving Savannah, Pooler, and coastal Georgia. He earned his medical degree at Loma Linda University and practiced emergency medicine before focusing his career on bariatric and metabolic medicine. At Scale Solutions he treats obesity as the chronic medical condition it is, combining GLP-1 therapy with nutrition counseling and long-term follow-up care.
What lab testing reveals about compounded semaglutide | Physician-led GLP-1 care | Bring your vial to a consultation